Patient demographic/clinical data and lesion countsa
| Sex | Age (yr) | Disease Duration (yr) | Treatment Type | Minimum WM Lesion Age (mo) | Cortical Lesion | WM Lesion | Mixed Lesion | |
|---|---|---|---|---|---|---|---|---|
| Patient | ||||||||
| 1 | F | 37 | 11 | Copaxoneb | 12 | 2 | 6 | 1 |
| 2 | M | 42 | 12 | Copaxone | 10 | 1 | 11 | 0 |
| 3 | F | 42 | 3 | Copaxone | 8 | 0 | 2 | 0 |
| 4 | F | 30 | 3 | Tysabric | 9 | 5 | 23 | 1 |
| 5 | F | 49 | 2 | Rebifd | 18 | 7 | 13 | 1 |
| 6 | M | 32 | 6 | Copaxone | 10 | 3 | 30 | 4 |
| 7 | M | 42 | 1 | Copaxone | 7 | 1 | 5 | 0 |
| 8 | F | 33 | 1 | Copaxone | 10 | 0 | 4 | 0 |
| 9 | F | 44 | 15 | No Treatment | 6 | 0 | 4 | 1 |
| 10 | F | 31 | 1 | No Treatment | 3 | 0 | 12 | 0 |
| 11 | F | 41 | 16 | Tysabri | 4 | 2 | 15 | 1 |
| 12 | F | 58 | 25 | Copaxone | 6 | 6 | 7 | 0 |
| 13 | M | 37 | 8 | Copaxone | 13 | 0 | 15 | 0 |
| 14 | M | 48 | 6 | Copaxone | 5 | 0 | 0 | 0 |
| Mean | 40.4 ± 7.9 | 7.9 ± 7.2 | 8.6 ± 4.0 | 1.9 ± 2.3 | 10.5 ± 8.4 | 0.64 ± 1.1 | ||
| Total | 27 | 147 | 9 |
↵a Patients 9 and 10 were not on any disease-modifying treatment at the time of their 7T scans. Patient 9 was on Tysabri, but it was stopped 6 months prior to her 7T scan. All patients had relapsing-remitting MS except patient 11, who was in a transitional stage between relapsing-remitting MS and secondary-progressive MS but was still being treated for relapsing-remitting MS. Patient 14 had lesions that all regressed before the 7T scan.
↵b Glatiramer acetate injection.
↵c Natalizumab.
↵d Interferon β-1a.